THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [12.28] ID: TIP-MED-000460 ⚠️ HIGH-ALERT / SPECIALIST SUPERVISION

Tacrolimus Ointment, Calcipotriol & Coal Tar / Salicylic Acid

Active Ingredient / Scientific Identity: Tacrolimus Ointment, Calcipotriol & Coal Tar / Salicylic Acid • Class: Topical Calcineurin Inhibitor (Steroid-Sparing Immunomodulator), Vitamin D3 Analogue & Keratolytics (Schedule H)

⚖️ Compare Profile
Generic / Entity NameTacrolimus Ointment, Calcipotriol & Coal Tar / Salicylic Acid ([12.28])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassTopical Calcineurin Inhibitor (Steroid-Sparing Immunomodulator), Vitamin D3 Analogue & Ker
Available Dosage FormsStandard hospital formulary strengths
Regulatory ClassificationSchedule H (Prescription Only — Registered Medical Practitioner)
Key Warning & Review DateHigh-alert hospital specialist agent; administer under close physiological and laboratory monitoring.
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H (Prescription Only — Registered Medical P🚨 Clinically High-Alert: Independent Dose & Route Verification Required👨‍⚕️ Specialist-Supervised Therapy

1. Clinical & Scientific Overview

Tacrolimus Ointment, Calcipotriol & Coal Tar / Salicylic Acid (TIP-MED-000460, Reference Code [12.28]) is classified under Emergency & Critical-Care Medicines as a Topical Calcineurin Inhibitor (Steroid-Sparing Immunomodulator), Vitamin D3 Analogue & Keratolytics (Schedule H). Within the Indian regulatory and compendial framework, it is governed under Schedule H (Prescription Only — Registered Medical Practitioner).

Verified Indian Market Examples / Compendial Status:
Representative Indian Formulations (for identification only): Tacrolimus Ointment: Tacroz / Tacroz Forte (Glenmark — 0.03%, 0.1%), Topgraf (Glaxo); Pimecrolimus 1% Cream: Elidel, Pacroma. | Strengths: Tacrolimus Ointment: **0.03% w/w** (Children 2–15 yr & sensitive adult facial skin) and **0.1% w/w** (Adults >=16 yr) (10 g, 20 g tube). Pimecrolimus Cream: **1.0% w/w**. Calcipotriol Ointment/Scalp Solution: **0.005% w/w (50 mcg/g)**.
Representative Indian Formulations (for identification only): Tacrolimus Ointment: Tacroz / Tacroz Forte (Glenmark — 0.03%, 0.1%), Topgraf (Glaxo); Pimecrolimus 1% Cream: Elidel, Pacroma. | Strengths: Tacrolimus Ointment: **0.03% w/w** (Children 2–15 yr & sensitive adult facial skin) and **0.1% w/w** (Adults >=16 yr) (10 g, 20 g tube). Pimecrolimus Cream: **1.0% w/w**. Calcipotriol Ointment/Scalp Solution: **0.005% w/w (50 mcg/g)**.
Dosage Forms & Available Strengths:
Standard hospital formulary strengths
Routes: Intravenous / Parenteral / Oral

3. Mechanism of Action & Pharmacodynamics

Established pharmacological class action (Topical Calcineurin Inhibitor (Steroid-Sparing Immunomodulator), Vitamin D3 Analogue & Keratolytics (Schedule H)): targets primary receptor, enzyme, ion-channel, or cellular pathway to achieve therapeutic efficacy in Tacrolimus Ointment (0.

4. Therapeutic Indications & Evidence-Supported Uses

  • Tacrolimus Ointment (0
  • 03%/0
  • 1%) & Pimecrolimus 1% Cream: **Steroid-Sparing Second-Line & Proactive Maintenance Therapy for Atopic Dermatitis (Eczema), Facial/Eyelid/Flexural Dermatitis, Vitiligo (repigmentation!), and Oral/Genital Lichen Planus** (**CRITICAL ADVANTAGE**: Topical Calcineurin Inhibitors inhibit T-cell I

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Tacrolimus Ointment / Pimecrolimus Cream: Apply a thin layer to affected skin **TWICE DAILY** until clearance, then switch to **Proactive Twice-Weekly Maintenance (e.g., Saturday & Sunday nights)** on previously affected eczema hotspots to prevent flares! (In Vitiligo: Apply BD for 3–6 months). (Duration: Active flare (2–6 weeks) followed by intermittent twice-weekly eczema maintenance or chronic vitiligo/psoriasis therapy)

Administration & Meal Timing: Oral (PO), Parenteral (IV / IM / SC as specified), Topical / Cutaneous | Food & Meal Timing: Independent of food; apply Tacrolimus to dry skin (wait 1–2 hours after bathing/moisturising if burning occurs); | Best Time of Day: Morning & Evening (BD) or Bedtime (Daivobet OD)

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Hospital pharmacokinetic profile; monitor therapeutic response and organ clearance.
Metabolism & Biotransformation:
Renal: Avoid Calcipotriol and large-area Salicylic Acid in severe CKD
Elimination & Renal Adjustment:
Renal: Avoid Calcipotriol and large-area Salicylic Acid in severe CKD
Hepatic Impairment Considerations:
Renal: Avoid Calcipotriol and large-area Salicylic Acid in severe CKD

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • TACROLIMUS & CALCIPOTRIOL WARNINGS: (1) Do not apply Tacrolimus/Pimecrolimus to active viral/bacterial skin infections (Herpes simplex [eczema herpeticum], warts, impetigo), Netherton syndrome, or children 3–6%) over large body areas in children or CKD causes systemic Salicylism** (tinnitus, hyperventilation, metabolic acidosis)!

Key Clinical Precautions: High-alert hospital specialist agent; administer under close physiological and laboratory monitoring.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Tacrolimus: **Transient local burning, warmth, stinging, or pruritus** at the application site during the first **3–5 days** of use (occurs in 30–50% due to initial substance-P release from cutaneous sensory nerves — **completely subsides after Day 4–5 as nerv
Serious / Dose-Limiting Adverse Effects:
  • Monitor for hemodynamic instability, organ toxicity, or severe hypersensitivity.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • CRITICAL INCOMPATIBILITY — SALICYLIC ACID INACTIVATES CALCIPOTRIOL!: **Salicylic Acid is acidic and chemically destroys/inactivates Calcipotriol on contact** — NEVER apply Salicylic Acid ointment/lotion at the same time as Calcipotriol (Daivonex)! (If descaling is needed, apply Salicylic Acid at a c

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Continuous clinical, hemodynamic, and organ-function laboratory monitoring.

Pharmacist Patient Counselling Points:

  • FOUR VITAL COUNTER RULES: (1) **Tacroz (Tacrolimus) and Elidel are NOT steroids** — they are completely safe to use on delicate skin like the **eyelids, face, neck, and skin folds** without thinning the skin or causing stretch marks

Storage, Stability & Dispensing Safeguards: Store in original moisture-protected packaging below 25°C–30°C (or 2°C–8°C cold chain if parenteral/biological vial specified in strengths: Tacrolimus Ointment: **0.03% w/w** (Children 2–15 yr & sensitive adult facial skin) and **0.1% w/w** (Adults >=16 yr) (10 g, 20 g tube). Pimecrolimus Cream: **1.0% w/w**. Calcipotriol Ointment/Scalp Solution: **0.005% w/w (50 mcg/g)**.). Missed-Dose Rule: Apply when remembered

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO • NCBI Bookshelf

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.